leadf
logo-loader
viewMindMed

MindMed announces R&D collaboration with Liechti Lab in Switzerland on psilocybin

The pair will seek to better understand and compare the altered states of consciousness induced by psilocybin and LSD

brain
There is increasing medical interest in LSD and psilocybin to treat mental illnesses but the drugs have never been accurately compared

Mind Medicine (MindMed) Inc (NEO:MMED) (OTCMKTS:MMEDF) (NEO:MMED) announced Thursday that the company has been conducting research and development work on psilocybin in collaboration with the University Hospital Basel's Liechti Lab in a study to better understand and compare the altered states of consciousness induced by psilocybin and LSD.

In a statement, MindMed said it is interested in understanding how psilocybin or LSD affects humans differently so that it can design better later stage trials or potentially even combine substances in future next-generation psychedelic-assisted therapies for patients.

As part of MindMed's exclusive license agreement with the University Hospital Basel in Switzerland, the company said it will retain an exclusive license to all intellectual property (IP) and any patents generated from data or findings in the study and related work on psilocybin, such as pharmacokinetic data and information on the metabolism. The study is anticipated to finish in the second quarter of 2021.

READ: MindMed submits application to up-list on Nasdaq as psychedelic medicine industry expands

The New York-based company noted that there is increasing medical interest in LSD and psilocybin for the treatment of mental illnesses but the drugs have never been accurately compared in a modern clinical setting to understand the differences they create in the alterations in one's mind. Psilocybin has a shorter duration of acute action but whether there are any differences in the quality of the experience, and as a result in the therapeutic potential, remains to be tested.

"Both LSD and psilocybin are thought to induce hallucinations mainly through the stimulation of the 5-HT2A receptor,” said MindMed President Dr Miri Halperin Wernli.

“However, it is known that there are differences in the receptor activation profiles between the two substances and these differences may induce different subjective effects. Therefore, with this study we will try to understand and compare the altered states of consciousness induced by the two substances and identify potential medicines for patients."

Dr Matthias Liechti who runs the lab added: "LSD and psilocybin are increasingly used in neuroscience and in psychiatry as pharmacological tools to induce and investigate alterations in waking consciousness and associated brain functions and also as potential medications. However, there are no modern studies comparing these two substances directly within the same clinical study and research subjects and using validated psychometric tools. We are aiming to compare the acute effects of the two substances including different doses and placebos to see whether there are differences in the alterations in mind produced by them."

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: MindMed

Price: 1.6 USD

OTCQB:MMEDF
Market: OTCQB
Market Cap: $449.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MindMed named herein, including the promotion by the Company of MindMed in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 30/6/20

3 min read